You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

93 search results for: quality of life

videoanimation

Type 2 Inflammation as the Common Thread in Multiple Diseases

5 min

Type 2 Inflammation

This video highlights type 2 inflammation as the common thread that links AD, asthma, CRSwNP, and EoE.

expert video

ERS 2024 | IL-33 A Promising Target

7 min

Pulmonology

Professor Klaus Rabe presents the latest clinical data on current and emerging biologic therapies targeting IL-33 in COPD.

expert video

ERS 2024 | Perspectives From the Evolving Biologic Landscape in COPD

20 min

Pulmonology

Professor Alberto Papi presents the latest clinical data on current and emerging biologics for COPD with type 2 inflammation.

expert video

CRSwNP: A Chronic Type 2 Inflammatory Disease

2 min

Rhinology

Prof. Peter Hellings describes how type 2 inflammation drives CRSwNP.

expert video

Scientific Advances in EoE and Impact on Clinical Practice

30 min

Gastroenterology

Expert gastroenterologist Dr. Evan Dellon highlights research and scientific advances in EoE and their impact on clinical practice.

expert video

Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?

2 min

Rhinology

This video clip from the EAACI 2024 symposium discusses whether patients with CRSwNP should undergo a surgery.

expert video

Treatment Goals, Current and Emerging Therapies in CSU

6 min

Dermatology

Drs. Maurer and Ensina delve into their thoughts on the latest treatment goals and emerging therapies for CSU in this illuminating interview.

expert video

Early Intervention in AD: Latest Clinical and Real-world Data

13 min

Dermatology

Highlights from ESPD 2023 ADVENT: Reviewing the current treatment landscape and the potential for early intervention in pediatric atopic dermatitis.

expert video

Targeting Type 2 Inflammation: Skin Barrier Normalization

11 min

Dermatology

Highlights from ESPD 2023 ADVENT: Uncovering how type 2 inflammation influences skin barrier dysfunction in atopic dermatitis.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Costa RicaChange country/region

93 search results for: quality of life

Type 2 Inflammation as the Common Thread in Multiple Diseases

ERS 2024 | IL-33 A Promising Target

ERS 2024 | Perspectives From the Evolving Biologic Landscape in COPD

CRSwNP: A Chronic Type 2 Inflammatory Disease

Scientific Advances in EoE and Impact on Clinical Practice

Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?

Treatment Goals, Current and Emerging Therapies in CSU

Early Intervention in AD: Latest Clinical and Real-world Data

Targeting Type 2 Inflammation: ​Skin Barrier Normalization​

Targeting Type 2 Inflammation: Skin Barrier Normalization